| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 06/21/2011 | US7964706 High affinity antibodies against HMGB1 and methods of use thereof |
| 06/21/2011 | US7964703 DNAX Cytokine Receptor Subunits (DCRS) 5 cytokine receptors modulators; multiple sclerosis, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, diabetes, psoriasis, sepsis or in allogeneic transplant; chronic Th1 mediated disease |
| 06/21/2011 | US7964567 Monomethylvaline compounds capable of conjugation to ligands |
| 06/21/2011 | US7964566 Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases |
| 06/21/2011 | US7964399 Nucleotide sequence vector that encodes a truncated Flk-1 protein which inhibits the binding of VEGF; uses for evaluate and screen of cancer drugs; as biodrug for modulating vasculogenesis and angiogenesis, inhibiting the tumor growth |
| 06/21/2011 | US7964371 Gastrin hormone immunoassays |
| 06/21/2011 | US7964366 Methods and compositions for detection of Ehrlichia chaffeensis (VLPT) |
| 06/21/2011 | US7964199 Therapeutic composition comprising a botulinum neurotoxin |
| 06/21/2011 | US7964195 Using immunoglobulin which preferentially binds cancer specific antigen (OVR110) as treatment for head and neck or endometrial cancer |
| 06/21/2011 | US7964194 Administering antibodies or antigen-binding fragments which bind mammalian chemokines |
| 06/21/2011 | US7964192 Prevention and treatment of amyloidgenic disease |
| 06/21/2011 | US7964191 Compositions and methods for the treatment of ophthalmic disease |
| 06/21/2011 | US7964190 Administering mixtures of antibodies and tumor necrosis factors, immunosuppressants, antibiotics, antiinflammatory agents, cytokines, angiogenesis inhibitors or fibroblast growth factors; prophylaxis of graft versus host disease |
| 06/21/2011 | CA2470731C Corticotropin releasing factor 2 receptor agonists |
| 06/21/2011 | CA2407556C Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| 06/21/2011 | CA2405290C Vaccine against cancerous diseases |
| 06/21/2011 | CA2342770C Ly6h gene |
| 06/21/2011 | CA2340328C Stable hypoxia inducible factor-1 alpha and method of use |
| 06/21/2011 | CA2299442C Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions |
| 06/21/2011 | CA2297408C Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof |
| 06/21/2011 | CA2280791C Immunological detection of prions |
| 06/21/2011 | CA2171336C Recombinant il4 antibodies useful in treatment of il4 mediated disorders |
| 06/16/2011 | WO2011072263A1 Pcsk9 antagonists |
| 06/16/2011 | WO2011071957A1 Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
| 06/16/2011 | WO2011071883A1 Anti-inflammatory antibodies and uses therefor |
| 06/16/2011 | WO2011071783A1 Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof |
| 06/16/2011 | WO2011071577A1 Anti-vegf-c antibodies and methods using same |
| 06/16/2011 | WO2011071574A2 Monoclonal antibodies against glycoprotein of ebola sudan boniface virus |
| 06/16/2011 | WO2011071099A1 Anticancer anti-mortalin peptide antibodies |
| 06/16/2011 | WO2011070443A1 Monoclonal antibodies that bind b7h6 and uses thereof |
| 06/16/2011 | WO2011070339A1 Method of treating disease |
| 06/16/2011 | WO2011070172A1 Anti-inflammatory agents directed against citrullinated epitopes |
| 06/16/2011 | WO2011070109A1 Trispecific therapeutics against acute myeloid leukaemia |
| 06/16/2011 | WO2011070088A1 Anti-c4.4a antibodies and uses thereof |
| 06/16/2011 | WO2011070045A1 Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| 06/16/2011 | WO2011070024A1 Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| 06/16/2011 | WO2011069799A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069798A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069797A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069796A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069795A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069794A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069614A1 Antibody that binds to h-1 parvovirus |
| 06/16/2011 | WO2011048503A3 Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof |
| 06/16/2011 | WO2011044311A3 Generation, characterization and uses thereof of anti-her 3 antibodies |
| 06/16/2011 | WO2011021014A3 Il1rap expression on acute and chronic myeloid leukemia cells |
| 06/16/2011 | WO2011020529A3 Antibodies for the detection of integrin complexes in ffpe material |
| 06/16/2011 | WO2011019932A9 Compositions and methods for the therapy and diagnosis of influenza |
| 06/16/2011 | WO2010142551A3 Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family |
| 06/16/2011 | US20110145941 Antibodies and derivatives thereof |
| 06/16/2011 | US20110145938 Method for generating monoclonal antibodies that recognize progenitor cells |
| 06/16/2011 | US20110144313 Membrane fusion proteins derived from reovirus |
| 06/16/2011 | US20110144312 Interleukin 10 receptor (il-10r) antibodies and methods of use |
| 06/16/2011 | US20110144310 Diagnosis of collagen IX destruction |
| 06/16/2011 | US20110144309 Manipulation of Cytokine Levels Using CD83 Gene Products |
| 06/16/2011 | US20110144308 Compositions and methods for humanization and optimization of n-glycans in plants |
| 06/16/2011 | US20110144307 Methods and Compositions Comprising Non-Natural Amino Acids |
| 06/16/2011 | US20110144281 Amphiphilic polymers having a cholane core |
| 06/16/2011 | US20110144163 Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents |
| 06/16/2011 | US20110143953 Synthetic Antibodies |
| 06/16/2011 | US20110143946 Method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent |
| 06/16/2011 | US20110143443 Isolsted Monoclonal - Associated Protein Tau and Kit |
| 06/16/2011 | US20110143428 Anti-vegf-c antibodies and methods using same |
| 06/16/2011 | US20110143421 Novel protease and use thereof |
| 06/16/2011 | US20110143379 Detection and quantitation of full-length thioredoxin (trx) and truncated thioredoxin (trx 80) in complex samples |
| 06/16/2011 | US20110143372 Antibodies against human epo receptor |
| 06/16/2011 | US20110143371 Procollagen c-proteinase enhancer (pcpe) biomarker for bone formation |
| 06/16/2011 | US20110143370 Nucleic Acids Encoding a Mammalian Raptor Polypeptide and Uses Therefor |
| 06/16/2011 | US20110143368 Tyrosine phosphorylation sites |
| 06/16/2011 | US20110143367 Antibodies against april as biomarkers for early prognosis of lymphoma patients |
| 06/16/2011 | US20110143333 Anti-chikungunya monoclonal antibodies and uses thereof |
| 06/16/2011 | US20110142911 HIV epitopes and pharmaceutical composition containing same |
| 06/16/2011 | US20110142872 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 06/16/2011 | US20110142865 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/16/2011 | US20110142864 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/16/2011 | US20110142861 Depletion of cd103 expressing cells for treatment of disorders |
| 06/16/2011 | US20110142860 Depletion of CD103 Expressing Cells for Treatment of Disorders |
| 06/16/2011 | US20110142859 Antibodies and immunoconjugates and uses therefor |
| 06/16/2011 | US20110142858 Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation |
| 06/16/2011 | US20110142853 Engineered Anti-IL-23p19 Antibodies |
| 06/16/2011 | US20110142852 Multispecific antibodies |
| 06/16/2011 | US20110142851 IL6 Immunotherapeutics |
| 06/16/2011 | US20110142849 Pcsk9 antagonists |
| 06/16/2011 | US20110142847 Methods of Eliciting Broadly Neutralizing Antibodies Targeting HIV-1 GP41 |
| 06/16/2011 | US20110142846 Method for diagnosing and treating emphysema |
| 06/16/2011 | US20110142845 NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE NOGO-66 RECEPTOR (NgR) AND USES THEREOF |
| 06/16/2011 | US20110142844 Anti-Extended Type I Glycosphingolipid Antibody, Derivatives Thereof And Use |
| 06/16/2011 | US20110142841 Compositions and methods for the treatment of systemic lupus erythematosis |
| 06/16/2011 | US20110142840 Compositions and Methods for Diagnosing and Treating Cancer |
| 06/16/2011 | US20110142838 Novel antibodies against cancer target block tumor growth, angiogenesis and metastatis |
| 06/16/2011 | US20110142825 Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity |
| 06/16/2011 | US20110142824 Antibodies Against Amyloid-Beta Peptide |
| 06/16/2011 | US20110142823 Humanized antibodies that recognize beta amyloid peptide |
| 06/16/2011 | US20110142822 Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof |
| 06/16/2011 | US20110142820 Novel Targets for Regulation of Angiogenesis |
| 06/16/2011 | US20110142792 Compositions for Increasing Polypeptide Stability and Activity, and Related Methods |
| 06/16/2011 | US20110142761 Il-1 binding proteins |
| 06/16/2011 | US20110142756 Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer |
| 06/16/2011 | US20110138888 Treatment of obesity |
| 06/16/2011 | CA2783926A1 Trispecific therapeutics against acute myeloid leukaemia |